India Court Rejects Cancer Drug Patent Bid - Presented by: The Aol. On Network

Residents in India's capital New Delhi form long queues at this pharmacy. The country is home to a drugs market that grows between 13 and 14 percent every year, making it an attractive investment for Western pharmaceutical companies. But a landmark court ruling could change that. On Monday, India's top court rejected a bid by Swiss drug-maker Novartis to win patent protection for its cancer drug, Glivec.



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
FCX $ 10.50 0.31 ▲ 3.04%
ATVI $ 29.22 1.29 ▲ 4.62%
BAC $ 16.36 0.08 ▼ 0.49%
AAPL $ 113.29 0.37 ▲ 0.33%
BTU $ 2.39 0.11 ▲ 4.82%
PBR $ 5.78 0.05 ▲ 0.87%
QQQ $ 105.62 0.02 ▼ 0.02%
INTC $ 28.42 0.70 ▲ 2.53%

As of 8/28/2015, 04:15 PM

Latest News Headlines

View All Latest Headlines